[
    [
        {
            "time": "",
            "original_text": "【东吴社服零售&医药 | 华熙生物】2021H1中报点评：21H1营收+104%，功能性护肤驱动收入增长",
            "features": {
                "keywords": [
                    "华熙生物",
                    "2021H1",
                    "中报",
                    "营收",
                    "104%",
                    "功能性护肤",
                    "收入增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "消费品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【东吴社服零售&医药 | 华熙生物】2021H1中报点评：21H1营收+104%，功能性护肤驱动收入增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]